Precigen believes that AI — combined with human interactions — is the future for rare disease marketing. The cell and gene therapy biotech has even tested out its hypothesis in its latest ad campaign.

REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc (RZLT). (Nasdaq: RZLT), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases ...

The MarketWatch News Department was not involved in the creation of this content. Industry veteran brings more than 30 years of experience launching therapies for neurological diseases, including ...

Mr. Hooks Brings Over Three Decades of Comprehensive Biopharmaceutical Marketing and Commercialization Expertise, Including the Launch of 21 New Products Spruce Biosciences, Inc. (Nasdaq: SPRB), a ...

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today ...

- Former Chimerix (CMRX, acquired by Jazz for $935 million) Senior Commercial Leader Michael Grabow led Go-To-Market Strategy and Launch for rare disease therapeutic MODEYSO® - - Rare disease ...

The 90-second commercial builds on the "Bent Carrot" campaign, launched in 2021, with creative that highlights a couple's journey from diagnosis to treatment. It spotlights the copay program designed ...

Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (Nasdaq: KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting ...

This campaign turns a birthday celebration into a chance to help children around the world. Every bid and every donation helps move research forward.” — Carol Schwimmer, ForeBatten Foundation CHAPEL ...

Vera Therapeutics, Inc. (NASDAQ:VERA) said on Wednesday that it had completed full enrollment (431 participants) in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA Nephropathy (IgAN ...